The Kosterlitz Centre for Therapeutics is leading the Horizon 2020 PET3D programme which will train the next generation of experts in the field of PET imaging
PET3D is funded by the European Commission under the H2020 - MSCA-ITN-2015 programme grant agreement No 675417 for a duration of 4 years (June 2016 - May 2020)
PET imaging is most commonly used as a diagnostic technique – radioactive ‘tracer’ molecules are injected into patients and PET is used to observe the functioning of the body and identify signs ofabnormalities, such as tumours, Alzheimer’s disease and heart conditions.
But PET imaging can also be used to ascertain the effectiveness of a drug before it goes into Phase 3 of development, so could put the brakes on ineffective drugs earlier and before large amounts of money are spent on further testing.
However, there is a world shortage in scientists with the necessary expertise to become research leaders in this area. All the major pharmaceutical companies use PET to develop drugs but the shortage means it is very difficult for companies and universities to recruit.
The PET3D project will cover all the main therapeutic areas - cancer, cardiovascular, dementia - and will train the next generation of experts in the field.